Skip to main content

Tempest Therapeutics shares head back to earth after 4,000% gain

Oncology company's stock drops more than 50% as it seeks partners to help advance investigational cancer treatment.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.